Protein Kinase N2 (PKN2/PRK2) is a critical Rho-associated serine/threonine kinase that integrates signals from Rho GTPases to regulate cell migration, adhesion, cell cycle progression, and tumor invasion. As a key player in the metastatic cascade of multiple solid tumors and a regulator of inflammatory myofibroblast activation, PKN2 has emerged as a high-value target for oncology, fibrosis, and cardiovascular therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PKN2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PKN2 Active Kinase Domain / Mutant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic assays. |
View PKN2 Products |
| Gene Delivery | PKN2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic assays. |
View PKN2 Products |
| Benchmark Ab | Anti-PKN2 Recombinant Antibody High affinity, sequence verified positive control for Western Blot, IP, and IHC. |
View PKN2 Products |
| Validator | PKN2 siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View PKN2 Products |
| Related Target A | PKN1 Highly homologous subfamily member required for selectivity profiling. |
View PKN1 Products |
| Related Target B | PKN3 Subfamily member involved in angiogenesis; critical for counter-screening. |
View PKN3 Products |
| Related Target C | RhoA Upstream activator of PKN2; essential for protein-protein interaction (PPI) assays. |
View RhoA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Subfamily Selectivity (PKN1/2/3) | Full panel of recombinant PKN subfamily proteins strictly verified by mass spectrometry and sequence analysis. |
| ROCK1/2 Counter-Screening | High-purity ROCK1 and ROCK2 homolog proteins available to rule out off-target kinase activity. |
| Lack of Controls | Sequence-defined benchmark recombinant antibodies included for assay standardization. |
| False Positives in Phenotypic Screens | Validated siRNA sets included for target-specific knockdown rescue experiments. |
Live PKN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PKN2 therapeutics is intensifying, with major players shifting focus from non-selective pan-kinase inhibitors to highly selective small molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation kinase inhibitors often suffer from cardiotoxicity and off-target effects due to cross-reactivity with ROCK1/2, the next wave of R&&D is targeting allosteric pockets and isoform-specific interactions with upstream Rho GTPases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Academic Consortia, Biotech Startups | Triple-Negative Breast Cancer, Prostate Cancer | Selectivity Assay (Need high-purity PKN1, PKN2, PKN3, and ROCK1/2 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) specialists | Metastatic Solid Tumors | Ubiquitination & Degradation Validation (Need Lentivirus for stable reporter cell lines) |
| Combination Therapies | Pharma Cooperatives | Idiopathic Pulmonary Fibrosis (IPF) | Pathway Synergism Validation (Need siRNA knockdown combined with small molecule panels) |